Revenues for the quarter totaled $20.1 million, up 8 percent from $18.6 million during the same period a year ago. Of those, $14.2 million came from genomics and toxicogenomics services, a 12-percent increase, while revenues from nonclinical contract research services decreased 2 percent, to $5.8 million.
The company's research and development expenses for the quarter were $1.4 million, up from $400,000 during the year-ago period.
Gene Logic's net loss for the quarter was $2.6 million, or $.08 per share, down 41 percent from $4.4 million, or $.14 per share, during last year's second quarter. Part of this improvement came from $500,000 in savings compared to last year's quarter due to a new income tax treaty between the
As of June 30, Gene Logic had $69 million in cash and cash equivalents, and $29 million in marketable securities.